Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseBenjamin Rolles, Valeria Santini, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 5
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseTed M. Getz, Aref Al‐Kali, Tariq Kewan et al.|Blood|2024Cited by 0
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscriptsTed M. Getz, Klaus H. Metzeler, Uma Borate et al.|Blood|2025Cited by 0